•Postbiotic Lactobacillus sakei CVL-001 promotes mucosal tolerance via NOD2-dependent programming of tolerogenic CD11c+ antigen-presenting cells
•Latent profile analysis of avoidant/restrictive food intake disorder in patients with inflammatory bowel disease in remission: A cross-sectional study
•Anti-TNF immunogenicity in a Middle Eastern inflammatory bowel disease cohort: prevalence, predictors and context-specific drug level thresholds
•Author's response to the editorial commentary, "TL1A and DR3 in IBD: from mucosal immunopathology to a new era of targeted therapy"
•The burden and unique patterns of extraintestinal manifestations in Chinese inflammatory bowel disease: a nationwide multicenter investigation
